The Institute for Clinical and Economic Review (ICER) has released its draft evidence report for the novel drugs plinabulin (BeyondSpring Pharmaceuticals) and trilaciclib (Cosela™, G1 Therapeutics). The report assessed the comparative clinical effectiveness and value of the two drugs that are intended to prevent chemotherapy-induced neutropenia and additional myelosuppressive effects. Both drugs had notable effects on symptoms of neutropenia, although Trilaciclib was less consistent.
According to the report, “We found that trilaciclib produced a small QALY gain versus no prophylaxis at a moderate added cost, resulting in estimates of $1,700,000 to $1,900,000 per QALY gained depending on line of therapy. Plinabulin increased QALYs, driven by an avoidance of febrile neutropenia-related deaths. The calculated threshold price per dose of plinabulin was $1,100 per cycle to reach the willingness to pay threshold of $100,000 per QALY gained.”
Read the entire report by clicking here.
(Source: ICER, January 25, 2022)